Bruker Announces that Institute Director, Biopharma Entrepreneur and Immunology Leader Dr. Eicke Latz will join its Board of Directors
Key Highlights
- ➤Eicke Latz joins Bruker’s board effective January 1, 2027
- ➤Latz has co-founded five biotechnology companies
- ➤Latz brings innate-immunity, biopharma, and medical-institute leadership experience
- ➤Bruker is expanding post-genomic life-science tools and diagnostics leadership
Expert Statements
Frank H. Laukien, Chairman, president and CEO of Bruker Corporation
“Eicke brings a rare combination of world-class disease biology leadership, remarkable biopharma entrepreneurial success, and medical institute strategic leadership to our board. As Bruker expands its leadership in post-genomic life-science tools for disease biology research, molecular diagnostics, and biopharma drug discovery and development, Eicke’s scientific-medical vision, biopharma insights, strategic and leadership experience will be very valuable to Bruker.”
Eicke Latz, Scientific Director of the German Rheumatology Research Center and Professor of Experimental Rheumatology at Charité Universitätsmedizin Berlin
“It’s a great honor to join the Board of Directors at Bruker Corporation, a company at the forefront of AI-accelerated, deep functional proteomics, multiomics and spatial biology research”
Eicke Latz, Scientific Director of the German Rheumatology Research Center and Professor of Experimental Rheumatology at Charité Universitätsmedizin Berlin
“I see Bruker as uniquely positioned to enable significant advancements in disease biology research, novel biomarker discovery, and next-generation proteomic molecular diagnostics, and I am very excited to contribute.”
Bruker Announces that Institute Director, Biopharma Entrepreneur and Immunology Leader Dr. Eicke Latz will join its Board of Directors
Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors is adding Eicke Latz, MD PhD to serve on its board of directors, effective as of January 1, 2027. Dr. Latz is an internationally recognized medical institute director, physician-scientist, successful biopharma entrepreneur, and innovation leader. His work is transforming the understanding of innate immunity and inflammation, while also advancing numerous therapeutic programs from discovery to clinical development.
Get started
Create a free account to read the full story.
